Biotech
MNKD Stock: Navigating the Nuances of MannKind's Future
Dive deep into MNKD stock. Explore its potential, risks, and what investors need to know about MannKind Corporation's trajectory and the latest market insights.
TXMD Stock Analysis: Inside TherapeuticsMD’s Royalty Pivot
Looking to invest in TXMD stock? Our deep-dive analysis covers TherapeuticsMD’s Q1 2026 earnings, the Mayne Pharma lawsuit, and its royalty business model.
SLS Stock: The Make-or-Break REGAL Catalyst and Pipeline Deep Dive
With the Phase 3 REGAL trial nearing database lock, sls stock is facing a high-stakes binary event. Read our deep dive into Sellas Life Sciences.
QNRX Stock: Is Quoin Pharmaceuticals a Buy, Sell, or Hold?
An in-depth investment analysis of QNRX stock. Explore Quoin Pharmaceuticals' rare disease pipeline, QRX003 trials, financial runway, and regulatory outlook.
AMGN Stock: Is Amgen's Obesity Pipeline a Buy in 2026?
Discover if AMGN is a buy in 2026. We analyze Amgen's Q1 2026 earnings, its revolutionary MariTide obesity drug, Horizon integration, and stock valuation.
ORMP Stock Analysis: Navigating Oramed's Landmark Pivot
Is ORMP stock a hidden value play or a speculative trap? Read our in-depth analysis of Oramed's Lifeward transaction, Scilex returns, and Q1 2026 earnings.
Amarin (AMRN) Stock Analysis: Supreme Court, Earnings & Buyout Potential
Is AMRN stock a deep-value buy or a risky trap? Explore Amarin's Q1 2026 earnings, the Hikma Supreme Court battle, and strategic buyout outlook.
AUPH Stock Analysis: Is Aurinia a Buy Under New Leadership?
AUPH stock is heating up after a total leadership overhaul, strong Q1 earnings, and the Kezar acquisition. Is Aurinia Pharmaceuticals undervalued? Find out.
IBRX Stock Forecast & Analysis: Growth, Risks, and Catalysts
Is IBRX stock a buy? Get the latest on ImmunityBio, from Anktiva's sales surge and crucial 2027 PDUFA date to FDA warning letters and class action lawsuits.
AVXL Stock: Is Anavex Life Sciences a Buy After May 2026 Shakeup?
Thinking about buying AVXL stock? Unpack the recent CEO termination, the Nasdaq delinquency notice, and the clinical future of blarcamesine.
Is REGN Stock a Buy Now? Valuation, Pipeline, and Risks
Thinking about investing in REGN stock? Discover if Regeneron's recent price dip, pipeline expansion, and cleared regulatory risks make it a buy today.
JAGX Stock: Q1 2026 Earnings, Nasdaq Survival, & Pipeline Updates
Is JAGX stock a buy or a speculative penny stock trap? Get the truth on Jaguar Health's Q1 2026 earnings, Nasdaq compliance struggle, and crofelemer pipeline.
BEAM Stock: Ultimate 2026 Investor Guide to Beam Therapeutics
An expert analysis of BEAM stock in 2026. Explore Beam Therapeutics' base editing breakthroughs, clinical catalysts, and mid-2029 financial cash runway.
AXSM Stock Analysis: Is Axsome a Buy After FDA Approval?
Is AXSM stock still a buy? Explore Axsome Therapeutics' Q1 2026 earnings, its massive new FDA approval for Auvelity, and its $18B clinical pipeline.
GILD Stock Analysis: Is Gilead Sciences a Buy in 2026?
Gilead Sciences (GILD) stock is a hot topic in 2026. Discover how its blockbuster HIV drug Yeztugo, oncology milestones, and a 2.5% dividend make it a buy.
NVTA Stock: The Rise, Fall, and Collapse of Invitae
What happened to NVTA stock? Discover how genetic testing giant Invitae Corp collapsed into Chapter 11, sold to Labcorp, and left shareholders with $0.
NVAX Stock Price Analysis: Is Novavax a Value Opportunity?
Explore the factors shaping the NVAX stock price in 2026, from the pivotal Sanofi partnership and Pfizer licensing deals to Wall Street's long-term forecast.
Avacta Share Price Forecast: Catalysts & Financials
An in-depth analysis of the Avacta share price (LSE:AVCT). Explore key pre|CISION pipeline updates, AVA6000 clinical trials, and the financial runway.
SIGA Stock Analysis: Is Undervalued Biodefense a Buy?
An in-depth SIGA stock analysis. Discover if SIGA Technologies' fortress balance sheet, TPOXX contracts, and Q1 2026 earnings make it a buy today.
TGTX Stock: Is TG Therapeutics a Buy After Upgraded Guidance?
TGTX stock is gaining momentum as TG Therapeutics raises 2026 Briumvi revenue guidance. Discover the valuation, pipeline catalysts, and investment risks.
BIIB Stock Analysis: Is Biogen a Buy After Pipeline Setbacks?
Biogen (BIIB) stock faces intense volatility in May 2026. Discover if the $5.6B Apellis acquisition and Leqembi offset recent trial failures.
EVFM Stock: The Financial Reality of Evofem Biosciences
Analyzing EVFM stock in 2026: Explore Evofem Biosciences' Q1 earnings, the failed Aditxt merger, reverse split history, and Phexxi's market potential.
CYDY Stock Analysis: Is CytoDyn Ready for a 2026 Turnaround?
An in-depth analysis of CYDY stock, exploring CytoDyn's recent legal settlements, leronlimab's CLOVER trial data, and its speculative investment outlook.
Regeneron Stock: Is the Post-Trial Selloff a Golden Buy?
With Regeneron stock trading at a discount following a late-stage trial failure, we explore its $1.2B Sanofi tailwind, Eylea HD, and long-term value.
Ginkgo Bioworks Stock Analysis: 2026 Pivot & DNA Stock Outlook
Is Ginkgo Bioworks stock a buy in 2026? Dive into DNA stock, the Nebula autonomous lab pivot, Q1 2026 earnings, and long-term synthetic biology forecasts.
MRNA Stock Price: Is Moderna a Buy as Pipeline Catalysts Heat Up?
Analyze the MRNA stock price in 2026. Explore key pipeline milestones, financial health, analyst price targets, and whether this biotech giant is a buy.
NVAX Yahoo Finance: Analyzing Novavax Stock, Earnings, and Strategy
Track NVAX Yahoo Finance data. Dive deep into Novavax's stock trends, Q1 2026 earnings, Sanofi and Pfizer partnerships, and the Matrix-M pivot.
VRTX Stock: Is Vertex Pharmaceuticals a Buy in 2026?
Vertex Pharmaceuticals (VRTX) stock is at a turning point as Casgevy and Journavx drive diversification. Discover if VRTX is a buy or sell in 2026.
SRNE Stock Update: What Happens to Sorrento Therapeutics Now?
Confused about SRNE stock? Discover the latest on Sorrento Therapeutics, the Vivasor asset transfer, the Liquidating Trust lawsuits, and Scilex dividends.
Teva Stock Forecast: Why the Turnaround is Finally Paying Off
Teva stock has surged to a decade-high in 2026. Discover why its Pivot to Growth strategy, Fitch rating upgrade, and pipeline make TEVA a high-conviction buy.
Novo Nordisk Stock (NVO) Analysis: Is the 2026 Selloff a Screaming Buy?
A deep-dive Novo Nordisk stock (NVO) analysis in 2026. Explore the impact of Wegovy price cuts, Eli Lilly competition, and CagriSema trial results.
NVAX Stock Forecast: Is Novavax a Buy on Its High-Margin Pivot?
NVAX stock deep dive: Is Novavax a buy in 2026? Discover how Q1 earnings, Pfizer and Sanofi licensing deals, and the Matrix-M adjuvant pivot reshape NVAX's value.
XBI Stock Forecast: Is This Biotech ETF a Buy in 2026?
Thinking of investing in XBI stock? Discover how this equal-weighted biotech ETF performs, its top holdings, key risks, and why it's a major player in 2026.